Cargando…

Therapeutic targets in alcohol-associated liver disease: progress and challenges

Alcohol-associated liver disease (ALD) is a complex disease with rapidly increasing prevalence. Although there are promising therapeutic targets on the horizon, none of the newer targets is currently close to an Food and Drug Administration approval. Strategies are needed to overcome challenges in s...

Descripción completa

Detalles Bibliográficos
Autores principales: Adekunle, Ayooluwatomiwa Deborah, Adejumo, Adeyinka, Singal, Ashwani K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176580/
https://www.ncbi.nlm.nih.gov/pubmed/37187673
http://dx.doi.org/10.1177/17562848231170946
_version_ 1785040459817549824
author Adekunle, Ayooluwatomiwa Deborah
Adejumo, Adeyinka
Singal, Ashwani K.
author_facet Adekunle, Ayooluwatomiwa Deborah
Adejumo, Adeyinka
Singal, Ashwani K.
author_sort Adekunle, Ayooluwatomiwa Deborah
collection PubMed
description Alcohol-associated liver disease (ALD) is a complex disease with rapidly increasing prevalence. Although there are promising therapeutic targets on the horizon, none of the newer targets is currently close to an Food and Drug Administration approval. Strategies are needed to overcome challenges in study designs and conducting clinical trials and provide impetus to the field of drug development in the landscape of ALD and alcoholic hepatitis. Management of ALD is complex and should include therapies to achieve and maintain alcohol abstinence, preferably delivered by a multidisciplinary team. Although associated with clear mortality benefit in select patients, the use of early liver transplantation still requires refinement to create uniformity in selection protocols across transplant centers. There is also a need for reliable noninvasive biomarkers for prognostication. Last but not the least, strategies are urgently needed to implement integrated multidisciplinary care models for treating the dual pathology of alcohol use disorder and of liver disease for improving the long-term outcomes of patients with ALD.
format Online
Article
Text
id pubmed-10176580
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-101765802023-05-13 Therapeutic targets in alcohol-associated liver disease: progress and challenges Adekunle, Ayooluwatomiwa Deborah Adejumo, Adeyinka Singal, Ashwani K. Therap Adv Gastroenterol Review Alcohol-associated liver disease (ALD) is a complex disease with rapidly increasing prevalence. Although there are promising therapeutic targets on the horizon, none of the newer targets is currently close to an Food and Drug Administration approval. Strategies are needed to overcome challenges in study designs and conducting clinical trials and provide impetus to the field of drug development in the landscape of ALD and alcoholic hepatitis. Management of ALD is complex and should include therapies to achieve and maintain alcohol abstinence, preferably delivered by a multidisciplinary team. Although associated with clear mortality benefit in select patients, the use of early liver transplantation still requires refinement to create uniformity in selection protocols across transplant centers. There is also a need for reliable noninvasive biomarkers for prognostication. Last but not the least, strategies are urgently needed to implement integrated multidisciplinary care models for treating the dual pathology of alcohol use disorder and of liver disease for improving the long-term outcomes of patients with ALD. SAGE Publications 2023-05-10 /pmc/articles/PMC10176580/ /pubmed/37187673 http://dx.doi.org/10.1177/17562848231170946 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Adekunle, Ayooluwatomiwa Deborah
Adejumo, Adeyinka
Singal, Ashwani K.
Therapeutic targets in alcohol-associated liver disease: progress and challenges
title Therapeutic targets in alcohol-associated liver disease: progress and challenges
title_full Therapeutic targets in alcohol-associated liver disease: progress and challenges
title_fullStr Therapeutic targets in alcohol-associated liver disease: progress and challenges
title_full_unstemmed Therapeutic targets in alcohol-associated liver disease: progress and challenges
title_short Therapeutic targets in alcohol-associated liver disease: progress and challenges
title_sort therapeutic targets in alcohol-associated liver disease: progress and challenges
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176580/
https://www.ncbi.nlm.nih.gov/pubmed/37187673
http://dx.doi.org/10.1177/17562848231170946
work_keys_str_mv AT adekunleayooluwatomiwadeborah therapeutictargetsinalcoholassociatedliverdiseaseprogressandchallenges
AT adejumoadeyinka therapeutictargetsinalcoholassociatedliverdiseaseprogressandchallenges
AT singalashwanik therapeutictargetsinalcoholassociatedliverdiseaseprogressandchallenges